ArticleCancer science2026
CircHECTD1 Promotes Cholangiocarcinoma Progression Through Interaction With SFPQ to Induce Autophagy.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Cholangiocarcinoma (CCA) constitutes a highly malignant tumor type demonstrating rising global incidence rates. Circular RNAs (circRNAs), characterized by their covalently bonded single-stranded loop configuration, have been identified as functional regulators across various cancer types. Previous studies have suggested circHECTD1's involvement in tumor processes, but its specific contributions and molecular pathways in CCA progression, particularly regarding autophagy regulation, remain unclear. Experimental data demonstrated significant upregulation of circHECTD1 in CCA cell lines, along with notable stability against RNase-mediated breakdown. From a functional perspective, increased circHECTD1 expression stimulated tumor cell growth, motility, invasive capacity, and autophagy processes, while triggering autophagosome formation. Mechanistically, circHECTD1 served as a molecular platform for the splicing factor SFPQ (proline- and glutamine-rich), facilitating SFPQ's binding to the ATG12 promoter regulatory region and enhancing the expression of ATG12 mRNA, resulting in increased transcriptional activity and enhanced mRNA durability, which in turn stimulated the autophagic process. When SFPQ was experimentally downregulated, this effect was diminished. Conversely, when autophagy was pharmacologically inhibited, the oncogenic effects mediated by circHECTD1 were effectively counteracted. These observations suggest that circHECTD1 plays a crucial role in the progression of CCA by forming a complex with SFPQ, which subsequently enhances both the transcription of ATG12 and the stability of ATG12 mRNA, thereby promoting autophagy and tumor progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.